Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055692 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
A Phase 2 study of Localized Unresectable Adult Primary Liver Cancer and Recurrent Adult Primary Liver Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT00055692: Completed Phase 2 study of Localized Unresectable Adult Primary Liver Cancer and Recurrent Adult Primary Liver Cancer, sponsored by National Cancer Institute (NCI).
NCT00055692 is a Phase 2 study of Localized Unresectable Adult Primary Liver Cancer and Recurrent Adult Primary Liver Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 46 participants, above the 20-participant average among 5 other Localized Unresectable Adult Primary Liver Cancer trials with a reported enrollment target (130% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055692, a Phase 2 study of Localized Unresectable Adult Primary Liver Cancer and Recurrent Adult Primary Liver Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is to see if bevacizumab works in treating patients who have unresectable nonmetastatic liver cancer that has not spread to the main portal vein. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them.
Conditions Studied
Interventions
- BIOLOGICAL bevacizumab
Study Locations (1)
New York
- Montefiore Medical Center - Moses Campus - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2003-02 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055692
The ClinicalTrials.gov registry entry for NCT00055692 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 20-participant average among 5 other Localized Unresectable Adult Primary Liver Cancer trials with a reported enrollment target (130% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Localized Unresectable Adult Primary Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which bevacizumab is the first listed.
NCT00055692 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00055692 about?
NCT00055692 is a clinical study titled "Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer". This phase II trial is to see if bevacizumab works in treating patients who have unresectable nonmetastatic liver cancer that has not spread to the main portal vein. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow ...
What is the current status of trial NCT00055692?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2003-02. Estimated completion is 2009-12.
What conditions does trial NCT00055692 study?
This clinical trial studies the following conditions: Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Adult Primary Hepatocellular Carcinoma.
What interventions are being tested in trial NCT00055692?
The interventions under investigation include: bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00055692?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00055692 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Localized Unresectable Adult Primary Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
COMPLETED · Phase 2
-
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
ACTIVE NOT RECRUITING
-
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
COMPLETED · Phase 1
-
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
COMPLETED · Phase 1
Explore more on PlainTrial
Localized Unresectable Adult Primary Liver Cancer
All registered trials for this condition
Recurrent Adult Primary Liver Cancer
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.